New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2013
07:21 EDTRTRXRetrophin to acquire Kyalin Biosciences, terms not disclosed
Retrophin announced that it will acquire privately-held Kyalin Biosciences, an early-stage company based in San Diego, CA, that is developing therapies targeting the core symptoms of autism and related conditions. Its lead product is an optimized intranasal delivery form of carbetocin, a synthetic analog of the naturally occurring peptide hormone, oxytocin. The deal is scheduled to close by year-end. As part of the transaction, Srinivas Rao, M.D., Ph.D., Founder and President of Kyalin Biosciences, joins Retrophin effective today as Executive Vice President, Head of Neuroscience with responsibility for central nervous system drug development.
News For RTRX From The Last 14 Days
Check below for free stories on RTRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2014
16:24 EDTRTRXOn The Fly: Closing Wrap
Subscribe for More Information
07:10 EDTRTRXRetrophin disappointed FDA won't grant expedited access to RE-024 for children
On Friday, April 11, Retrophin received an update from RE-024 clinical investigators that, despite several investigator-sponsored IND filings for RE-024 in the United States, the FDA has been unwilling to grant a clinical trial through this mechanism. The company intends to file a company-sponsored IND in May or June 2014, with a Phase I clinical trial in PKAN patients beginning in June or July 2014. The company continues to support efforts to launch an investigator-sponsored trial outside of the United States. The company said, “While we are disappointed the FDA has been unwilling to grant expedited access to RE-024 for children with a lethal disease, we respect its decision and are motivated by the enthusiastic and brave physicians and patients who desperately want access to this promising molecule. The small delay is frustrating to all of our stakeholders, but we expect the issue will be resolved in the near term and we are taking steps to grow our R&D infrastructure to avoid similar experiences in the future.”
07:09 EDTRTRXRetrophin raises FY14 revenue view to $19M-$21M from $10M-$12M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use